Company intelligence / Profile preview

VeraCell

Cambridge, Massachusetts, United Statesveracell.com ↗

Ownership: Private
Employees: ~357
Development stage: Other

Overview

Vericel has demonstrated clinical efficacy with its commercialized products. MACI has shown benefit in repairing cartilage defects of the knee, while Epicel provides permanent skin replacement for severe burn victims. NexoBrid, licensed from MediWound, offers enzymatic debridement for severe thermal burns and received FDA approval for both adult and pediatric use.

Therapeutic areas: DermatologyRheumatology
Modalities: Cell therapyBiologicAutologous cell therapyCultured epidermal autograft (Epicel)Autologous cultured chondrocytes on porcine collagen membrane (MACI)
Industry: Biotech

Partnerships

MediWound (exclusive North American licensee for NexoBrid)

Beyond the preview

Go deeper on VeraCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VeraCell.

Explore the full profile